New CEO to Medivir

The Board of the Swedish biotech company Medivir has appointed the successor to the current CEO Lars Adlersson.
The new CEO is Ron Long, who starts his new job on February 1st. Ron Long was elected to Medivir’s Board in 2007. He has a broad experience from the pharmaceutical and life science industry.

Ron Long is presently an Executive Director of Sky Medical, Non Executive Director of DxS, the Chairman of Procognia Israel and Managing Director and owner of Scicona. He was formally Chairman of Kudos Pharmaceuticals, Deputy Chairman of The Automation Partnership, Senior Independent Director Asterand, and Non Executive Director of Gyros and Biacore.

Ron Long joined the main Board of Amersham in August 1990 as Commercial Director. He then went on to be appointed Managing Director Life Sciences in 1996 and CEO for Amersham Pharmacia Biotech from 1997 until June 2000 when he was appointed Vice Chairman of the Group until his retirement from Amersham in June 2001.

Prior to joining Amersham , Ron worked for 22 years with the Wellcome Foundation holding Divisional Director appointments in Wellcome Biotechnology, Coopers Animal Health and was Group Managing Director of Calmic International immediately before joining the Main Board at Amersham in 1990.
Kommentera en artikel
Utvalda artiklar


Sänd till en kollega